Ginkgo Bioworks Holdings, Inc. (DNA)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Ginkgo Bioworks Holdings, Inc. reported revenue of $170.16M, down 25.1% from the prior year. The company ran a net loss, with a net margin of -183.8%. It held $1.12B in total assets against $611.11M in total liabilities.
Key ratios (FY2025)
-185.3%
Operating margin
-183.8%
Net margin
-61.5%
Return on equity
-25.1%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $170.16M | $227.04M | $251.46M | $477.71M | $313.84M | $76.66M | $54.18M |
| Operating Income | -$315.28M | -$559.76M | -$864.41M | -$2.21B | -$1.83B | -$137.03M | -$71.60M |
| Net Income | -$312.76M | -$547.03M | -$892.87M | -$2.10B | -$1.83B | -$126.61M | -$119.33M |
| EPS (Diluted) | $-5.64 | $-10.54 | $-18.37 | $-50.20 | $-1.39 | $-0.10 | $-0.10 |
| Total Assets | $1.12B | $1.38B | $1.67B | $2.54B | $2.07B | $675.15M | — |
| Total Liabilities | $611.11M | $661.39M | $568.19M | $803.04M | $503.61M | $205.10M | — |
| Shareholders' Equity | $508.59M | $716.06M | $1.10B | $1.74B | $1.51B | $461.38M | — |
| Cash & Equivalents | $167.20M | $561.57M | $944.07M | $1.32B | $1.55B | $380.80M | $495.29M |
| Operating Cash Flow | -$171.06M | -$319.58M | -$295.50M | -$252.20M | -$253.82M | -$135.83M | -$44.66M |
| Capital Expenditures | $7.67M | $62.54M | $40.80M | $52.27M | $56.52M | $57.82M | $22.22M |
| Shares Outstanding | 55.46M | 51.89M | 48.61M | 42.00M | 1.36B | 1.27B | 1.15B |